Current Cardiology Reports

, Volume 3, Issue 5, pp 401–407 | Cite as

Treatment of dyslipidemia in pre- and postmenopausal women with and without known atherosclerotic cardiovascular disease

  • Vera Bittner


Cardiovascular disease is the primary cause of death among women in the United States, in part due to a very high prevalence of dyslipidemia. Clinical trials have shown that low-density lipoprotein cholesterol-lowering therapy can decrease angiographic progression of coronary disease and decrease clinical events among women and men. Although hormone replacement therapy has beneficial effects on the lipoprotein profile, its role in cardiovascular disease prevention remains unclear. The recently released Third Report of the National Cholesterol Education Program Expert Panel provides detailed guidelines for the management of dyslipidemia in women, with a focus on low-density lipoprotein cholesterol and intensity guided by risk of cardiovascular events.


Pravastatin Lovastatin Colesevelam Major Coronary Event Post Coronary Artery Bypass Graft 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    American Heart Association: 2001 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2000.Google Scholar
  2. 2.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. NIH Publication No. 93-3095, September 1993.Google Scholar
  3. 3.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497. New US guidelines for the assessment and treatment of hyperlipidemia.Google Scholar
  4. 4.
    Liao Y, McGee DL, Cooper RS: Prediction of coronary heart disease mortality in blacks and whites: pooled data from two national cohorts. Am J Cardiol 1999, 84:31–36.PubMedCrossRefGoogle Scholar
  5. 5.
    Manolio TA, Pearson TA, Wenger NK, et al.: Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol 1992, 2:161–176.PubMedCrossRefGoogle Scholar
  6. 6.
    Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovascular Risk 1996, 3:213–219.CrossRefGoogle Scholar
  7. 7.
    Kane JP, Malloy MJ, Ports TA, et al.: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990, 264:3007–3012.PubMedCrossRefGoogle Scholar
  8. 8.
    Waters D, Higginson L, Gladstone P, et al., for the CCAIT Study Group: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994, 89:959–968.PubMedGoogle Scholar
  9. 9.
    Ballantyne CM, Herd JA, Schein JR, et al.: Treatment of patients with mild to moderate hypercholesterolemia: Lipoprotein and Coronary Atherosclerosis Study (LCAS). CVR&R 1998, 12–24.Google Scholar
  10. 10.
    Campeau L, Hunninghake DB, Knatterud GL, et al., and the Post CABG Trial Investigators: Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI Post Coronary Artery Bypass Graft Clinical Trial. Circulation 1999, 99:3241–3247.PubMedGoogle Scholar
  11. 11.
    Byington RP, Jukema JW, Salonen JT, et al.: Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995, 92:2419–2425.PubMedGoogle Scholar
  12. 12.
    Miettinen TA, Pyoeraelae K, Olsson A, et al., for the Scandinavian Simvastatin Study Group: Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation 1997, 96:4211–4218.PubMedGoogle Scholar
  13. 13.
    Lewis SJ, Sacks FM, Mitchell JS, et al., for the CARE Investigators: Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial. J Am Coll Cardiol 1998, 32:140–146.PubMedCrossRefGoogle Scholar
  14. 14.
    The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357.CrossRefGoogle Scholar
  15. 15.
    Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/TexCAPS Research Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998, 279:1615–1622.PubMedCrossRefGoogle Scholar
  16. 16.
    LaRosaJC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340–2346. Meta-analysis of the major statin trials that provides subgroup data by gender and age.CrossRefGoogle Scholar
  17. 17.
    Fonarow GC, French WJ, Parsons LS, et al., for the National Registry of Myocardial Infarction 3 Participants: Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001, 103:38–44.PubMedGoogle Scholar
  18. 18.
    Aronow HD, Topol EJ, Roe MT, et al.: Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001, 357:1063–1068.PubMedCrossRefGoogle Scholar
  19. 19.
    Stenestrand U, Wallentin L, for the dish Register of Cardiac Intensive Care Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001, 285:430–436.PubMedCrossRefGoogle Scholar
  20. 20.
    Schwartz GG, Olsson AG, Ezekowitz MD, et al., for the Miocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Study Investigators: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711–1718.PubMedCrossRefGoogle Scholar
  21. 21.
    Byington RP, Evans GW, Espeland MA, et al., for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group: Effects of lovastatin and warfarin on early carotid atherosclerosis. Circulation 1999, 100:e14-e17.PubMedGoogle Scholar
  22. 22.
    Plehn JF, Davis BR, Sacks FM, et al., for the CARE Investigators: Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) Study. Circulation 1999, 99:216–223.PubMedGoogle Scholar
  23. 23.
    Ross SD, Allen IE, Connelly JE, et al.: Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999, 159:1793–1802.PubMedCrossRefGoogle Scholar
  24. 24.
    Bittner V, Simon JA, Fong J, et al.: Correlates of high HDL cholesterol among women with coronary heart disease. Am Heart J 2000, 139:288–296.PubMedGoogle Scholar
  25. 25.
    Hu FB, Stampfer MJ, Manson JAE, et al.: Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000, 343:530–537.PubMedCrossRefGoogle Scholar
  26. 26.
    Hu FB, Stampfer MJ, Manson JAE, et al.: Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med 1997, 337:1491–1499.PubMedCrossRefGoogle Scholar
  27. 27.
    Anderson JW, Allgood LD, Lawrence A, et al.: Cholesterollowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am J Clin Nutr 2000, 71:472–479.PubMedGoogle Scholar
  28. 28.
    Miettinen TA, Puska P, Gylling H, et al.: Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995, 333:1308–1312.PubMedCrossRefGoogle Scholar
  29. 29.
    Gylling H, Radhakrishnan R, Miettinen TA: Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine. Circulation 1997, 96:4226–4231.PubMedGoogle Scholar
  30. 30.
    Vuorio AF, Gylling H, Turtola H, et al.: Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation. Arterioscler Thromb Vasc Biol 2000, 20:500–506.PubMedGoogle Scholar
  31. 31.
    Blair SN, Capuzzi DM, Gottlieb SO, et al.: Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000, 86:46–52.PubMedCrossRefGoogle Scholar
  32. 32.
    Stefanick ML, Mackey S, Sheehan M, et al.: Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 1998, 339:12–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Warner JG, Brubaker PH, Zhu Y, et al.: Long-term (5-year) changes in HDL cholesterol in cardiac rehabilitation patients: do sex differences exist? Circulation 1995, 92:773–777.PubMedGoogle Scholar
  34. 34.
    Anderson RE, Wadden TA, Bartlett SJ, et al.: Effects of lifestyle activity vs. structured aerobic exercise in obese women: a randomized trial. JAMA 1999, 281:335–340. Randomized trial of two physical activity interventions that shows that lifestyle activity, which may be easier to implement for women, especially older women, is associated with significant benefit.CrossRefGoogle Scholar
  35. 35.
    Olson MB, Kelsey SF, Bittner V, et al., for the Women’s Ischemia Syndrome Evaluation (WISE) Study Group: Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect. A report from the NHLBI-sponsored WISE Study. J Am Coll Cardiol 2000, 36:1565–1571. Provocative data on the impact of weight cycling on HDL-C in women. The study is limited by its cross-sectional design and the retrospective ascertainment of weight cycling, but points to a potentially very important side effect of repeated unsuccessful attempts to control body weight over time.PubMedCrossRefGoogle Scholar
  36. 36.
    Fogelholm M, Kukkonen-Harjula K, Nenonen A, Pasanen M: Effects of walking training on weight maintenance after a very-low-energy diet in premenopausal obese women. Arch Intern Med 2000, 160:2177–2184.PubMedCrossRefGoogle Scholar
  37. 37.
    Ory SJ, Field CS, Herrmann RR, et al.: Effects of long-term transdermal administration of estradiol on serum lipids. Mayo Clin Proc 1998, 73:735–738.PubMedCrossRefGoogle Scholar
  38. 38.
    The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995, 273:199–208.CrossRefGoogle Scholar
  39. 39.
    Hulley S, Grady D, Bush T, et al., for the Heart and Estrogen/ progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605–613.PubMedCrossRefGoogle Scholar
  40. 40.
    Herrington DM, Reboussin DM, Broshnihan KB, et al.: Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000, 343:522–529.PubMedCrossRefGoogle Scholar
  41. 41.
    Bittner V: Estrogen, lipids and cardiovascular disease: no easy answers. J Am Coll Cardiol 2001, 37:431–433.PubMedCrossRefGoogle Scholar
  42. 42.
    Shlipak MG, Simon JA, Vittinghoff E, et al.: Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart events after menopause. JAMA 2000, 283:1845–1852. Subgroup analysis of the HERS trial. Points out that Lp(a) is a significant predictor of events among postmenopausal women with coronary heart disease. Also suggests that women with high Lp(a) may benefit from hormone replacement therapy.PubMedCrossRefGoogle Scholar
  43. 43.
    Davidson MH, Testolin LM, Maki KC, et al.: A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med 1997, 157:1186–1192.PubMedCrossRefGoogle Scholar
  44. 44.
    Sbarouni E, Kyriakides ZS, Kremastinos DTH: The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998, 32:1244–1250.PubMedCrossRefGoogle Scholar
  45. 45.
    Herrington DM, Werbel BL, Riley WA, et al.: Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1999, 33:2030–2037.PubMedCrossRefGoogle Scholar
  46. 46.
    Cox JL: Lipid-lowering drugs in pregnancy and lactation. In Cardiac Problems in Pregnancy, edn 3. Edited by Elkayam U, Gleicher N. New York: Wiley-Liss; 1998:445–449.Google Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Vera Bittner
    • 1
  1. 1.Division of Cardiovascular DiseaseUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations